Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Investors: Take Advantage of Double Fed Tax Credits on Critical Minerals Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Fate Therapeutics Inc FATE

Healthcare Biotechnology
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of programmed cellular immunotherapies for patients with cancer and autoimmune disorders. It uses human induced pluripotent stem cells (iPSCs) generated from its iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:FATE)

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

GlobeNewswire November 8, 2023

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

GlobeNewswire October 25, 2023

Fate Therapeutics to Present at Upcoming September Investor Conferences

GlobeNewswire August 31, 2023

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

GlobeNewswire August 8, 2023

Grabar Law Office Investigates Claims on Behalf of Shareholders of Fate Therapeutics, Inc. (FATE)

Newsfile August 3, 2023

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

GlobeNewswire July 28, 2023

FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE

Business Wire June 30, 2023

FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Business Wire June 21, 2023

Fate ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Business Wire June 8, 2023
View More News ››

Opinion & Analysis (NDAQ:FATE)

Fate Therapeutics Shares Rise 10% as First Person Treated with Its Anti-Cancer Therapy

Streetwise Reports April 7, 2020

Seven biotech names on the upswing: 2016 small-cap biotech watchlist update

The Life Sciences Report March 11, 2016
View More Opinion ››

Bullboard Posts (NDAQ:FATE)

RE:Article on Finpedia.co

Here's the link:  Fate Therapeutics
wiltonio - January 2, 2019

Article on Finpedia.co

Finpedia is a stock market wiki that is assembling stock background reports for every publicy-traded company in the world. Here is the...
wiltonio - January 2, 2019

Insider buying nov 28

Significant insider buying by director Rastetter William. $999,998 worth of shares on open market but no avg price/share information...
Wepoundem - November 30, 2016

RE:RE:Anyone holding this stock?

It's tough to find good info or insight on this play. I've been in and out for a year now.   Hoping it can hold above $3...
Wepoundem - November 14, 2016

RE:Anyone holding this stock?

Yeah, I've got a few shares. Had a good day on Friday. I mostly follow it on Yahoo but the Yahoo Finance page has been so screwed up...
Pandora - November 12, 2016

Anyone holding this stock?

Is anyone else holding or trading FATE? Its been a decent play for trading on volatility well building a long position. They seem to have...
Wepoundem - November 9, 2016
View more Bullboard ››

Vanstar Mining Resources Inc.

Vanstar Mining Resources Inc.

Vanstar Mining’s Nelligan gold project joint venture with IAMGOLD (25% VSR/75% IMG), located 60 kilometres SW of Chibougamau, ...
View More »